ATE519500T1 - Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung - Google Patents

Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung

Info

Publication number
ATE519500T1
ATE519500T1 AT02770472T AT02770472T ATE519500T1 AT E519500 T1 ATE519500 T1 AT E519500T1 AT 02770472 T AT02770472 T AT 02770472T AT 02770472 T AT02770472 T AT 02770472T AT E519500 T1 ATE519500 T1 AT E519500T1
Authority
AT
Austria
Prior art keywords
mutants
immunodeficiency virus
human immunodeficiency
envelope glycoproteins
compositions
Prior art date
Application number
AT02770472T
Other languages
English (en)
Inventor
John P Moore
James Binley
Min Lu
William Olson
Norbert Schulke
Jason Gardner
Paul Maddon
Rogier Sanders
Original Assignee
Progenics Pharm Inc
Cornell Res Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharm Inc, Cornell Res Foundation Inc filed Critical Progenics Pharm Inc
Application granted granted Critical
Publication of ATE519500T1 publication Critical patent/ATE519500T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
AT02770472T 2001-09-06 2002-09-06 Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung ATE519500T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31777501P 2001-09-06 2001-09-06
US31776401P 2001-09-06 2001-09-06
US31790901P 2001-09-06 2001-09-06
US31791001P 2001-09-06 2001-09-06
US37026402P 2002-04-05 2002-04-05
US37041002P 2002-04-05 2002-04-05
PCT/US2002/028331 WO2003022869A2 (en) 2001-09-06 2002-09-06 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof

Publications (1)

Publication Number Publication Date
ATE519500T1 true ATE519500T1 (de) 2011-08-15

Family

ID=27559706

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02770472T ATE519500T1 (de) 2001-09-06 2002-09-06 Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung

Country Status (7)

Country Link
US (1) US20050089526A1 (de)
EP (1) EP1461079B8 (de)
JP (1) JP2005502350A (de)
AT (1) ATE519500T1 (de)
AU (1) AU2002335709B8 (de)
CA (1) CA2459426A1 (de)
WO (1) WO2003022869A2 (de)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710173B1 (en) 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
AU2002335710A1 (en) * 2002-04-05 2003-10-27 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
GB0228939D0 (en) * 2002-12-12 2003-01-15 Univ Nottingham Peptide presentations for human immunodeficiency disease vaccines
WO2005054272A2 (en) * 2003-11-26 2005-06-16 Tanox, Inc. Human immunodeficiency virus entry inhibitor assay
EP1773303A2 (de) * 2004-05-25 2007-04-18 Chimeracore, Inc. Selbstmontierendes nanopartikel-wirkstofffreisetzungssystem
EP1766097A4 (de) * 2004-06-15 2008-03-19 Progenics Pharm Inc Hiv-1-neutralisierende antikörper, ausgelöst durch einen trimeren hiv-1-hyllglycoproteinkomplex
EP2088155A1 (de) * 2004-12-29 2009-08-12 Seattle Biomedical Research Institute Hetero-oligomere HIV-Hüllproteine
CA2648581A1 (en) * 2006-04-07 2008-09-12 Chimeros, Inc. Compositions and methods for treating b- cell malignancies
CA2655929A1 (en) * 2006-06-19 2007-12-27 Progenics Pharmaceuticals, Inc. Processes for recovering stabilized formulations of trimers of retroviral envelope (env) proteins
EP2040747A4 (de) * 2006-06-19 2010-08-25 Progenics Pharm Inc Lösliche stabilisierte trimere hiv-hüllproteine und ihre verwendung
US7939083B2 (en) * 2006-10-23 2011-05-10 Progenics Pharmaceuticals Inc. Soluble, stabilized, proteolytically cleaved, trimeric HIV-1 gp140 proteins comprising modifications in the N-terminus of the gp41 ectodomain
CA2683063A1 (en) * 2007-04-09 2008-10-16 Chimeros, Inc. Self-assembling nanoparticle drug delivery system
EP2478766A3 (de) * 2007-05-09 2012-08-15 Burnham Institute for Medical Research Wirtsproteinasen als Ziel für eine therapeutische Strategie gegen virale und bakterielle Krankheitserreger
WO2010120874A2 (en) 2009-04-14 2010-10-21 Chimeros, Inc. Chimeric therapeutics, compositions, and methods for using same
US20120164232A1 (en) * 2009-09-09 2012-06-28 Tokyo Institute Of Technology Construct coated with virus coat-constituting protein and method for producing same
WO2012003234A2 (en) * 2010-06-30 2012-01-05 Torrey Pines Institute For Molecular Studies Env trimer immunogens
US10675346B2 (en) 2010-11-12 2020-06-09 Children's Medical Center Corporation Antigenic polypeptides comprising pre-hairpin intermediate conformations of HIV-1 GP41
WO2012149038A1 (en) * 2011-04-25 2012-11-01 Advanced Bioscience Laboratories, Inc. Truncated hiv envelope proteins (env), methods and compositions related thereto
CA2847888A1 (en) 2011-09-09 2013-03-14 Biomed Realty, L.P. Methods and compositions for controlling assembly of viral proteins
EP2765138B1 (de) * 2012-11-05 2018-01-10 International Aids Vaccine Initiative Hüllglykoprotein von HIV-1
US20160122395A1 (en) * 2013-03-15 2016-05-05 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. Immunogenic compositions and a process for producing same
WO2015127108A1 (en) * 2014-02-19 2015-08-27 Duke University Trimeric hiv-1 envelopes compositions and uses thereof
AU2018304502B2 (en) * 2017-07-19 2022-03-31 Janssen Vaccines & Prevention B.V. Trimer stabilizing HIV envelope protein mutations
WO2019152746A2 (en) 2018-01-30 2019-08-08 Emory University Compositions and methods for promoting immune responses to human immunodeficiency virus
JP7658584B2 (ja) * 2019-05-23 2025-04-08 マサチューセッツ インスティテュート オブ テクノロジー リガンドの発見およびレトロウイルス表面ディスプレーを介した遺伝子送達
WO2020243166A1 (en) * 2019-05-28 2020-12-03 The Regents Of The University Of California Th1-polarizing adjuvants for enhancing immunogenicity of hiv antigens
EP4245767A4 (de) 2020-11-12 2025-04-30 Xiamen University Modifiziertes membranprotein des menschlichen immundefizienzvirus und verwendung davon
AU2024353243A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Antigen binding polypeptides
AU2024353718A1 (en) 2023-09-25 2026-04-09 Kelonia Therapeutics, Inc. Compositions for treating cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUT62316A (en) * 1990-09-25 1993-04-28 Hiver Ltd Process for producing aids vaccine and for diagnosing aids
US5474914A (en) * 1992-07-29 1995-12-12 Chiron Corporation Method of producing secreted CMV glycoprotein H
US5674698A (en) * 1992-09-14 1997-10-07 Sri International Up-converting reporters for biological and other assays using laser excitation techniques
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
US6171596B1 (en) * 1993-12-10 2001-01-09 The United States Of America As Represented By The Department Of Health And Human Services Oligomeric HIV-1 envelope glycoproteins
US6716429B1 (en) * 1997-10-01 2004-04-06 Dana-Farber Cancer Institute, Inc. Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp 41 glycoprotein ectodomain
AU2221600A (en) * 1998-12-31 2000-07-31 Chiron Corporation Improved expression of hiv polypeptides and production of virus-like particles
US6710173B1 (en) * 1999-06-25 2004-03-23 Progenics Pharmaceuticals, Inc. Stabilized viral envelope proteins and uses thereof
HK1046911A1 (zh) * 1999-06-25 2003-01-30 Progenics Pharmaceuticals, Inc. 经稳定的病毒外膜蛋白质及其使用
AU2002335710A1 (en) * 2002-04-05 2003-10-27 Progenics Pharmaceuticals, Inc. Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
JP2006509039A (ja) * 2002-12-03 2006-03-16 ユニバーシティ オブ マサチューセッツ 多価初代ｈｉｖ−１糖タンパク質ｄｎａワクチンおよびワクチン接種方法
US7737067B2 (en) * 2005-12-20 2010-06-15 Chevron U.S.A. Inc. Regeneration of ionic liquid catalyst

Also Published As

Publication number Publication date
EP1461079A4 (de) 2006-09-20
EP1461079A2 (de) 2004-09-29
AU2002335709B8 (en) 2008-12-18
CA2459426A1 (en) 2003-03-20
WO2003022869A3 (en) 2004-07-22
AU2002335709B2 (en) 2008-11-27
WO2003022869A2 (en) 2003-03-20
US20050089526A1 (en) 2005-04-28
EP1461079B1 (de) 2011-08-10
EP1461079B8 (de) 2012-03-14
JP2005502350A (ja) 2005-01-27

Similar Documents

Publication Publication Date Title
ATE519500T1 (de) Mutanten von hüllglykoproteinen des human immunodeficiency virus und deren verwendung
CO5700784A2 (es) Polipeptidos de virus de papiloma humano y composiciones in- munogenas
DE69824013D1 (de) Impfstoff gegen hpv
ATE508635T1 (de) Virusvektoren und ihre verwendung bei therapeutischen methoden
ATE386538T1 (de) Kombinierte verwendung von faktor vii polypeptiden und faktor viii polypeptiden
ATE231917T1 (de) Immunresponse gegen hpv antigene erregt von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einen expressionsvektor fähig zur expression dieser proteine
ATE328068T1 (de) Papillomavirus vakzine
PE20040554A1 (es) Vacunas que comprenden proteinas de fusion
ES2150595T3 (es) Procedimiento de preparacion de un vector viral de por lo menos 20 kb por recombinacion homologa intermolecular en una celula procariota.
ATE380822T1 (de) Funf-helix protein
DE69729786D1 (de) Hochkonzentrierte, lyophilisierte und flüssige faktor-ix formulierungen
CY1105963T1 (el) Συνθεσεις καψομepιδιακου εμβολιου του ιου του θηλωματος και μεθοδοι χρησης
FI951138A7 (fi) Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa
DE59410380D1 (de) Endosomolytisch wirksame partikel
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
PL363071A1 (pl) Sposoby i kompozycje dla zmniejszenia replikacji HIV-1
WO2003087757A3 (en) Particle-bound human immunodeficiency virus envelope clycoproteins and related compositions and methods
ATE551069T1 (de) Mucin-fusionspolypeptid-vakzine, zusammensetzungen und ihre verwendung
BR0312889A (pt) Polipeptìdeo t20 peguilado
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DE69013011D1 (de) Bcrf1-proteine als inhibitoren von interferon-g(g).
ATE356207T1 (de) Humanes btrcp protein
EP1578772A4 (de) Cytokine und cytokinrezeptoren mit reduzierter immunogenität
WO2002034909A3 (en) Engineered chimera of hiv protein fragments and uses thereof
MX2025007937A (es) Proteinas 3 f del virus de la parainfluenza humana estabilizadas prefusion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties